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LETTER TO THE EDITOR
Comment on: PML in patients with systemic
lupus erythematosus: a systematic literature
review
Sir,
We read with interest the report ‘Progressive
multifocal leukoencephalopathy in patients with
systemic lupus erythematosus: a systematic litera-
ture review’ and wish to emphasize that lymphope-
nia, which may be the most important risk factor
for progressive multifocal leukoencephalopathy
(PML), failed to be mentioned.
In their thorough literature review, Henegar
et al.1 found that most systemic lupus erythemato-
sus (SLE) patients (32 out of 35) were on immuno-
suppressant therapy (IST) at the time of PML
diagnosis. Even though the IST type was discrimi-
nated, individual duration and eﬀect of IST on the
immune system could not be analysed.
A recent case report from our units was asso-
ciated with a fatal outcome.2 The patient had
severe CD4þ T cell lymphopenia. Our review of
the literature revealed that information about
lymphocyte counts was scarce, but when available
lymphopenia was invariably present in SLE
patients with PML.
PML was initially described in patients subjected
to chemotherapy3 and is a feared complication of
idiopathic CD4þ T cell lymphopenia.4 Altogether,
such compelling evidence leads us to believe that in
order to prevent PML in SLE, lymphocyte counts
should be frequently monitored and IST adjusted
in order to avoid severe lymphopenia. Current rec-
ommendations support maintaining a total count
above 1000 106/L,5 but in current practice we
believe the management of lymphopenia in SLE
remains an unmet need.
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